Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lymphoma, also known as malignant lymphoma, is a general term for a group of malignant tumors originating from the lymphopoietic system. It is one of the most common tumors in China. In 2020, there were 544,352 new cases of non-Hodgkin lymphoma (NHL) worldwide, ranking 13th among all new cases of malignancies.

Roche has expanded the Global Access Program, originally established to increase availability of HIV diagnostics in underserved countries, to include diagnostic tests for tuberculosis, hepatitis, and human papillomavirus (HPV). Increased acc

Life science reagents and tools company Abcam announced today that it has acquired genome editing technologies firm EdiGene's live cell line and lysates portfolio.

A federal judge will limit 10x Genomics' ability to sell and market its single-cell analysis solution.

Agilent Technologies said today that it has agreed to acquire privately held life science instrumentation manufacturer BioTek Instruments for $1.17 billion in cash.

Thermo Fisher Scientific today reported a 4 percent increase in second-quarter revenues, driven by growth across its business segments.

Qiagen on Wednesday afternoon reported preliminary second quarter financial results ahead of its full Q2 earnings release next week, and said that it is adjusting its full-year financial targets downward due to lower-than-expected sales of i

PerkinElmer said after the close of the market on Monday that its total revenues in the second quarter grew 3 percent year over year but missed the consensus Wall Street estimate.

Illumina reported after the close of the market on Monday that its second quarter 2019 revenues grew 1 percent year over year.

China's National Medical Products Administration (NMPA) recently extended approval of the Roche Cobas EGFR Mutation Test v2 to include the use of plasma samples for the detection of EGFR mutations in patients with non-small cell lung cancer,

RNAi therapeutics firm Alnylam Pharmaceuticals and consumer genetics firm 23andMe will offer free genetic test kits to first-degree family members of 23andMe customers who have a TTR variant known to cause hereditary amyloidosis.